Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03653507
Title A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Astellas Pharma Global Development, Inc.

gastroesophageal junction adenocarcinoma

stomach cancer

gastric adenocarcinoma

gastroesophageal cancer


Capecitabine + Oxaliplatin

Capecitabine + Oxaliplatin + Zolbetuximab

Age Groups: senior | adult
Covered Countries USA | CAN

No variant requirements are available.